ClinicalTrials.gg
CompletedNCT00270816Updated Dec 19, 2018

Interferon ß-1b Treatment by Cyclical Administration

A Phase 2/3 interventional study of Interferon-ß-1b and Interferon ß-1b in Multiple Sclerosis, sponsored by S. Andrea Hospital. Completed at 1 site in Italy. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by S. Andrea Hospital · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.

Enrollment
141st of 230
60 · median 115
Started
2005
with 3 others
Phase 2/3
4 of 289
none open now
Registered
10th of 289
by date
Lead sponsor
8 of 289
S. Andrea Hospital

Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 141st largest by enrollment of the 230 interventional ones that give a count, is one of 4 that started in 2005, is one of 4 in phase 2/3, and was the 10th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in Multiple Sclerosis with a site in Italy, or all of them as a file.
02

Study summary

The therapy with Interferon-ß-1b reduces the inflammatory component of multiple sclerosis with positive effects on the disease course. The 8 MUI dose at alternate days is kept constant for years. About 1/3 of patients suspend treatment by three years due to side effects or suspected or accepted ineffectiveness. The main objective of the study is to verify the safety and effectiveness of a cyclical administration (a month of suspension after two of treatment) from the beginning of treatment. There is the possibility that a scheme envisaging therapy free intervals can reduce the onset of negative feedbacks (antagonising the drug therapeutic effect) compared to the standard administration protocol. This might also result in an increase of the drug effectiveness and/or in a longer duration of effectiveness itself. Finally, cyclical administration allows patients to spend actual periods of "therapeutic vacation", with positive psychological effects.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Interferon-ß-1b
  • Therapy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients affected by remitting Multiple Sclerosis who had at least a relapse in the last year of the disease.
  • Satisfying general clinical conditions according to the researcher. Adequate hepatic function. Capacity to use adequate techniques during the study.

Exclusion criteria

Exclusion Criteria:

  • Any other disease that might better explain signs and symptoms of the patient.
  • Any other disability condition that might interfere with the clinical evolution.
  • History of to natural or recombinant interferon or to human albumin.
  • heart diseases and not controlled like dysrhythmias, angina pectoris or congestive heart failure.
  • Not adequately controlled epilepsy.
  • Inability, according to the examining commission, to grant a complete compliance with the protocol requirements for the whole study.
  • Previous therapies modifying the disease course in the last six months.
  • therapies in the last 3 months.
  • Pregnancy, lactation, serological positivity to the pregnancy test during the screening period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    interferon beta cyclical administration

    Interferon ß-1b Treatment by Cyclical Administration

    Drug: Interferon-ß-1b

  • Active comparator
    Interferon ß-1b Treatment

    Interferon ß-1b Treatment

    Drug: Interferon ß-1b

Interventions

  • DrugInterferon-ß-1b

    250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months

  • DrugInterferon ß-1b

    250 micrograms (8 MIU) administered subcutaneously (sc) every other day

06

What researchers measure

Primary outcomes

  1. number of gad-enhancing lesions (CELs) in T1

    Group (cyclic withdrawal vs full regimen) differences in the cumulative number of CELs

    Time frame: baseline and after 12 months

Secondary outcomes

  1. number of new and enlarging T2 lesions

    Group (cyclic withdrawal vs full regimen) differences in new and enlarging T2 lesions

    Time frame: baseline and after 12 months

  2. volume of T1 lesions (black holes)

    Group (cyclic withdrawal vs full regimen) differences in T1 lesion volume (black holes)

    Time frame: baseline and after 12 months

  3. relapse rate

    Group (cyclic withdrawal vs full regimen) differences in relapse rate

    Time frame: baseline and after 12 months

07

Study locations

1 site
  • Azienda Ospedaliera S. Andrea, II Facoltà di Medicina e Chirurgia, Università di Roma "La Sapienza"
    Rome, 00139, Italy
08

References and documents

Publications

  • Steinman L. Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol. 2001 Oct;13(5):597-600. doi: 10.1016/s0952-7915(00)00266-1. PubMed 11544011 ↗
  • Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology. 1997 May;48(5):1446-8. doi: 10.1212/wnl.48.5.1446. PubMed 9153489 ↗
  • Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler. 2000 Apr;6(2):86-90. doi: 10.1177/135245850000600206. PubMed 10773853 ↗
  • Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000 Oct;1(4):311-6. doi: 10.1038/79758. PubMed 11017102 ↗
  • Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999 Feb 19;283(5405):1183-6. doi: 10.1126/science.283.5405.1183. PubMed 10024247 ↗
  • Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol. 1999 Oct 15;163(8):4284-91. PubMed 10510367 ↗
  • McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7. doi: 10.1002/ana.1032. PubMed 11456302 ↗
  • Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G, Bozzao L, Fieschi C. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):251-8. doi: 10.1136/jnnp.61.3.251. PubMed 8795595 ↗
  • Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G. Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. Front Neurol. 2019 Jul 16;10:695. doi: 10.3389/fneur.2019.00695. eCollection 2019. PubMed 31379701 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2005 to primary completion in Aug 2010, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2005
First posted
Dec 28, 2005
StartActual
Nov 2005
Primary completionActual
Aug 2010
CompletionActual
Jan 2011
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00270816
Lead sponsor
S. Andrea Hospital
Collaborators
Italian Multiple Sclerosis Foundation
Responsible party
Giovanni Ristori (MD, S. Andrea Hospital) — Principal investigator
First posted
Dec 28, 2005
Start date
Nov 2005
Primary completion
Aug 2010
Completion
Jan 2011
Last update
Dec 19, 2018

Study contacts

Marco Salvetti, MD
study director · S.Andrea Hospital, University of Rome "La Sapienza"

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion